Background The mechanisms by which any upper respiratory virus, including SARS-CoV-2,
impairs chemosensory function are not known. COVID-19 is frequently associated with …

Abstract Coronavirus disease 2019 (COVID‐19) is still propagating a year after the start of
the pandemic. Besides the complications patients face during the COVID‐19 disease period …

Abstract Reports of Guillain-Barré syndrome (GBS) have emerged during the Coronavirus
disease 2019 (COVID-19) pandemic. This epidemiological and cohort study sought to …

Background and purpose Mounting evidence supports an association between Guillain−
Barré syndrome spectrum (GBSs) and severe acute respiratory syndrome coronavirus 2 …

Increasing literature has linked COVID‐19 to peripheral nervous system (PNS) diseases. In
addition, as we move from the pandemic to the vaccination era, literature interest is shifting …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the aetiologic agent of the
coronavirus disease 2019 (COVID-19), is now rapidly disseminating throughout the world …

In the wake of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pandemic, an increasing number of patients with neurological disorders, including Guillain …

Abstract mRNA vaccines against SARS-CoV-2 are remarkably effective. Limited information
exists about the incidence of adverse events following immunization (AEFI) with their use …

Guillain–Barré syndrome (GBS) is an autoimmune disorder of the peripheral nervous system
that typically develops within 4 weeks after infection. In addition to conventional infectious …

Background and purpose Many single cases and small series of Guillain–Barré syndrome
(GBS) associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) …